Levels of anti-topoisomerase I antibody correlated with short onset of cardiopulmonary involvement in Thai systemic sclerosis patients.
Anti-topoisomerase I
Autoantibody
Interstitial lung disease
Scleroderma and related disorders
Systemic sclerosis
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
06 May 2024
06 May 2024
Historique:
received:
28
02
2024
accepted:
02
05
2024
medline:
7
5
2024
pubmed:
7
5
2024
entrez:
6
5
2024
Statut:
epublish
Résumé
Anti-topoisomerase-I antibody (ATA) is associated with disease severity and internal organ involvement in patients with systemic sclerosis (SSc). The correlation between ATA levels and the clinical course of SSc is unclear. We aimed to determine the correlation between ATA level and survival time and the onset of internal organ fibrosis in SSc patients. This historical cohort study was conducted in adult SSc patients with quantitative tests of ATA between January 2019 and December 2022. Patients with overlap syndrome and no quantitative ATA test were excluded. According to the sample size calculation, and 10% compensated for missing data, a total of 153 patients were needed. The respective mean age on the study date and median ATA level was 59.9 ± 11.3 years and 370 U/mL (range 195-652). Most cases (107 cases; 69.9%) were the diffuse cutaneous SSc subset. According to a multivariable analysis, the ATA titer had a negative correlation with the onset of cardiac involvement (Rho - 0.47, p = 0.01), and had a positive correlation with skin thickness progression (Rho 0.39, p = 0.04). Eleven cases exhibited ATA levels < 7 U/mL and outlier ATA levels were excluded, 142 cases were included in the sensitivity analysis, and multivariable analysis showed the correlation between early onset of ILD and cardiac involvement (Rho - 0.43, p = 0.03 and Rho - 0.51, p = 0.01, respectively). The ATA level was correlated with neither the survival time nor the onset of renal crisis in both analyses. High ATA levels were correlated with a short onset of ILD and cardiac involvement and the presence of extensive skin tightness. Quantitative tests of ATA could serve as an effective tool for identifying patients at risk of an unfavorable prognosis.
Identifiants
pubmed: 38710779
doi: 10.1038/s41598-024-61159-3
pii: 10.1038/s41598-024-61159-3
doi:
Substances chimiques
DNA Topoisomerases, Type I
EC 5.99.1.2
Autoantibodies
0
TOP1 protein, human
EC 5.99.1.2
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
10354Informations de copyright
© 2024. The Author(s).
Références
Systemic Sclerosis, Scleroderma—ClinicalKey. https://www.clinicalkey.com/#!/content/book/3-s2.0-B9780123849298000332
Barnes, J. & Mayes, M. D. Epidemiology of systemic sclerosis: Incidence, prevalence, survival, risk factors, malignancy, and environmental triggers. Curr. Opin. Rheumatol. 24, 165–170 (2012).
doi: 10.1097/BOR.0b013e32834ff2e8
pubmed: 22269658
LeRoy, E. C. et al. Scleroderma (systemic sclerosis): Classification, subsets and pathogenesis. J. Rheumatol. 15, 202–205 (1988).
pubmed: 3361530
Piantoni, S., Franceschini, F., Fredi, M., Andreoli, L. & Tincani, A. Topoisomerase I (SCL 70) autoantibodies, Chapter 29. In Autoantibodies 3rd edn (eds Shoenfeld, Y. et al.) 239–245 (Elsevier, 2014). https://doi.org/10.1016/B978-0-444-56378-1.00029-0 .
doi: 10.1016/B978-0-444-56378-1.00029-0
Reveille, J. D., Solomon, D. H., American College of Rheumatology Ad Hoc Committee of Immunologic Testing Guidelines. Evidence-based guidelines for the use of immunologic tests: Anticentromere, Scl-70, and nucleolar antibodies. Arthritis Rheum. 49, 399–412 (2003).
doi: 10.1002/art.11113
pubmed: 12794797
van den Hoogen, F. et al. 2013 classification criteria for systemic sclerosis: An American College of Rheumatology/European League Against Rheumatism Collaborative Initiative. Ann. Rheum. Dis. 72, 1747–1755 (2013).
doi: 10.1136/annrheumdis-2013-204424
pubmed: 24092682
Malignancies in Italian patients with systemic sclerosis positive for anti-RNA polymerase III antibodies. J. Rheumatol. https://www.jrheum.org/content/38/7/1329.long
Hanke, K. et al. Diagnostic value of anti-topoisomerase I antibodies in a large monocentric cohort. Arthritis Res. Ther. 11, R28 (2009).
doi: 10.1186/ar2622
pubmed: 19232127
pmcid: 2688262
Sato, S., Hamaguchi, Y., Hasegawa, M. & Takehara, K. Clinical significance of anti-topoisomerase I antibody levels determined by ELISA in systemic sclerosis. Rheumatology 40, 1135–1140 (2001).
doi: 10.1093/rheumatology/40.10.1135
pubmed: 11600743
Kuwana, M., Kaburaki, J., Mimori, T., Kawakami, Y. & Tojo, T. Longitudinal analysis of autoantibody response to topoisomerase I in systemic sclerosis. Arthritis Rheum. 43, 1074–1084 (2000).
doi: 10.1002/1529-0131(200005)43:5<1074::AID-ANR18>3.0.CO;2-E
pubmed: 10817562
Srikamud, S. et al. Incidence of anti-topoisomerase I antibody seroconversion and clinical association in systemic sclerosis. Asia-Pac. J. Sci. Technol. 26 (2021).
Foocharoen, C. et al. Incidence and prevalence of systemic sclerosis in Thailand in year 2017–2020: A database from the Ministry of Public Health. Clin. Rheumatol. 42, 1767–1774 (2023).
doi: 10.1007/s10067-023-06550-7
pubmed: 36894730
pmcid: 9998257
Foocharoen, C. et al. Clinical characteristics and outcomes of 566 Thais with systemic sclerosis: A cohort study. Int. J. Rheum. Dis. 23, 945–957 (2020).
doi: 10.1111/1756-185X.13859
pubmed: 32420701
Foocharoen, C. et al. Relevance of clinical and autoantibody profiles in systemic sclerosis among Thais. Int. J. Rheum. Dis. 20, 1572–1581 (2017).
doi: 10.1111/1756-185X.13060
pubmed: 28296274
Roberts-Thomson, P. J. et al. Scleroderma in South Australia: Epidemiological observations of possible pathogenic significance. Intern. Med. J. 31, 220–229 (2001).
doi: 10.1046/j.1445-5994.2001.00048.x
pubmed: 11456035
Englert, H. et al. Systemic sclerosis prevalence and mortality in Sydney 1974–88. Aust. N. Z. J. Med. 29, 42–50 (1999).
doi: 10.1111/j.1445-5994.1999.tb01587.x
pubmed: 10200812
Tamaki, T., Mori, S. & Takehara, K. Epidemiological study of patients with systemic sclerosis in Tokyo. Arch. Dermatol. Res. 283, 366–371 (1991).
doi: 10.1007/BF00371817
pubmed: 1796818
Geirsson, A. J., Steinsson, K., Guthmundsson, S. & Sigurthsson, V. Systemic sclerosis in Iceland. A nationwide epidemiological study. Ann. Rheum. Dis. 53, 502–505 (1994).
doi: 10.1136/ard.53.8.502
pubmed: 7944633
pmcid: 1005388
Hashimoto, A., Endo, H., Kondo, H. & Hirohata, S. Clinical features of 405 Japanese patients with systemic sclerosis. Mod. Rheumatol. 22, 272–279 (2012).
doi: 10.3109/s10165-011-0515-7
pubmed: 21874591
Poormoghim, H. et al. Systemic sclerosis: Demographic, clinical and serological features in 100 Iranian patients. Rheumatol. Int. 33, 1943–1950 (2013).
doi: 10.1007/s00296-013-2668-5
pubmed: 23344826
Ferri, C. et al. Systemic sclerosis: Demographic, clinical, and serologic features and survival in 1,012 Italian patients. Medicine (Baltimore) 81, 139–153 (2002).
doi: 10.1097/00005792-200203000-00004
pubmed: 11889413
Tyndall, A., Mueller-Ladner, U. & Matucci-Cerinic, M. Systemic sclerosis in Europe: First report from the EULAR Scleroderma Trials And Research (EUSTAR) group database. Ann. Rheum. Dis. 64, 1107 (2005).
doi: 10.1136/ard.2005.036038
pubmed: 15958775
pmcid: 1755555
Delisle, V. C., Hudson, M., Baron, M., Thombs, B. D., The Canadian Scleroderma Research Group. Sex and time to diagnosis in systemic sclerosis: An updated analysis of 1,129 patients from the Canadian scleroderma research group registry. Clin. Exp. Rheumatol. 32, 10–14 (2014).
Reveille, J. D. et al. Systemic sclerosis in 3 US ethnic groups: A comparison of clinical, sociodemographic, serologic, and immunogenetic determinants. Semin. Arthritis Rheum. 30, 332–346 (2001).
doi: 10.1053/sarh.2001.20268
pubmed: 11303306
EliA Scl-70S Well. Thermo Fisher Scientific https://www.thermofisher.com/phadia/wo/en/product-catalog.html?articleNumber=14-5637-01®ion=TH
Foocharoen, C. et al. Inter- and intra-observer reliability of modified Rodnan Skin Score Assessment in Thai systemic sclerosis patients: A validation for multicenter scleroderma cohort study. J. Med. Assoc. Thailand 98, 1082 (2015).
Pongkulkiat, P., Thinkhamrop, B., Mahakkanukrauh, A., Suwannaroj, S. & Foocharoen, C. Skin model for improving the reliability of the modified Rodnan skin score for systemic sclerosis. BMC Rheumatol. 6, 33 (2022).
doi: 10.1186/s41927-022-00262-2
pubmed: 35650637
pmcid: 9161481
Korn, J. H. et al. Digital ulcers in systemic sclerosis: Prevention by treatment with bosentan, an oral endothelin receptor antagonist. Arthritis Rheum. 50, 3985–3993 (2004).
doi: 10.1002/art.20676
pubmed: 15593188
Young, A., Namas, R., Dodge, C. & Khanna, D. Hand impairment in systemic sclerosis: Various manifestations and currently available treatment. Curr. Treat. Opt. Rheumatol. 2, 252–269 (2016).
doi: 10.1007/s40674-016-0052-9
Walsh, S. L. F. et al. Role of imaging in progressive-fibrosing interstitial lung diseases. Eur. Respir. Rev. 27, 180073 (2018).
doi: 10.1183/16000617.0073-2018
pubmed: 30578332
pmcid: 9488692
Simonneau, G. et al. Haemodynamic definitions and updated clinical classification of pulmonary hypertension. Eur. Respir. J. 53, 1801913 (2019).
doi: 10.1183/13993003.01913-2018
pubmed: 30545968
pmcid: 6351336
Janda, S., Shahidi, N., Gin, K. & Swiston, J. Diagnostic accuracy of echocardiography for pulmonary hypertension: A systematic review and meta-analysis. Heart 97, 612–622 (2011).
doi: 10.1136/hrt.2010.212084
pubmed: 21357375
Humbert, M. et al. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: Developed by the task force for the diagnosis and treatment of pulmonary hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS). Endorsed by the International Society for Heart and Lung Transplantation (ISHLT) and the European Reference Network on rare respiratory diseases (ERN-LUNG). Eur. Heart J. 43, 3618–3731 (2022).
doi: 10.1093/eurheartj/ehac237
pubmed: 36017548
Savarino, E. et al. Gastrointestinal involvement in systemic sclerosis. Presse Med. 43, e279-291 (2014).
doi: 10.1016/j.lpm.2014.03.029
pubmed: 25179275
Mirsaeidi, M., Barletta, P. & Glassberg, M. K. Systemic sclerosis associated interstitial lung disease: New directions in disease management. Front. Med. 6, 248 (2019).
doi: 10.3389/fmed.2019.00248
Foocharoen, C. et al. Clinical differences between Thai systemic sclerosis patients with positive versus negative anti-topoisomerase I. Int. J. Rheum. Dis. 19, 312–320 (2016).
doi: 10.1111/1756-185X.12492
pubmed: 25293362
Kakkar, V. et al. Type 1 interferon activation in systemic sclerosis: A biomarker, a target or the culprit. Curr. Opin. Rheumatol. 34, 357–364 (2022).
doi: 10.1097/BOR.0000000000000907
pubmed: 36125916
pmcid: 9594133
Nógrádi, Á. et al. Prognostic value of right atrial stiffness in systemic sclerosis. Clin. Exp. Rheumatol. https://doi.org/10.55563/clinexprheumatol/3vdmeh (2022).
doi: 10.55563/clinexprheumatol/3vdmeh
pubmed: 36135944
Hu, P. Q., Fertig, N., Medsger, T. A. & Wright, T. M. Correlation of serum anti-DNA topoisomerase I antibody levels with disease severity and activity in systemic sclerosis. Arthritis Rheum. 48, 1363–1373 (2003).
doi: 10.1002/art.10977
pubmed: 12746909
Nishioka, K. et al. Epidemiological analysis of prognosis of 496 Japanese patients with progressive systemic sclerosis (SSc). Scleroderma Research Committee Japan. J. Dermatol. 23, 677–682 (1996).
doi: 10.1111/j.1346-8138.1996.tb02680.x
pubmed: 8973032
Hissaria, P. et al. Survival in scleroderma: Results from the population-based South Australian Register. Intern. Med. J. 41, 381–390 (2011).
doi: 10.1111/j.1445-5994.2010.02281.x
pubmed: 20546058